Our little company, a biotech with a dividend, a profitable company in its own right may finally be getting some deserved recognition in the market place. Who knows with this very illiquid stock but yesterdays' announcement which went under the radar is very significant. Firstly, they have the cash to fund it all themselves in collaboration with experts.
Secondly, Technegas is used around the world already in countries such as China and Canada. The results from this new study, if proven to be extremely beneficial represent something momentous due to the serious issues involved in COPD.
Thirdly, in the biotech sector we have the behemoths earning stacks, the much smaller ones making a profit, the even smaller speculative ones that could be huge and unfortunately the odd disaster.
CYC is the second, and with this study, a defacto clinical phase 3 probably trial using real humans, we have the potential to go up the ladder.
Very exciting times folks and again, the market cap of $61 million for what they have is in my opinion low, but what this new trial could do for them simply astounds me. If they don't announce some sort of overseas collaboration as a seed funder to aid growth, I will damn well eat my hat. That is after a few vanilla Magnums. Then I will buy a truck load for the family, and the refrigerated truck to keep them there over summer.
CYC Price at posting:
88.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)